Response-selective C5a agonists: Differential effects on neutropenia and hypotension in the rat

Anna J. Short, Natalii J. Paczkowski, Shawn M. Vogen, Sam D. Sanderson, Stephen M. Taylor

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Some in vivo activities of two complement C5a agonist analogues have been evaluated by measuring changes in blood pressure and neutropenia in the rat and comparing the results with their receptor affinities in peritoneal macrophages and polymorphonuclear leucocytes (PMNs). In vitro C5a receptor (C5aR) binding experiments showed that YSFKPMPLaR and YSFKD(NMeNle)PlaR had similar affinities for the macrophage C5aR (IC50 0.2, 0.1 μM respectively). In PMNs, the affinity of YSFKPMPLaR (IC50 0.1 μM) was similar to that in macrophages, whereas the affinity of YSFKD(NMeNle)PLaR for the PMN C5aR was > 100 μM. Given i.v., YSFKD(NMeNle)PLaR had similar activity to YSFKPMPLaR on blood pressure but did not cause neutropenia. These results demonstrate selectivity of a new C5a agonist in vitro, which is paralleled in vivo. The results suggest the possibility of developing selective agonists of C5a for in vivo use in humans.

Original languageEnglish (US)
Pages (from-to)511-514
Number of pages4
JournalBritish Journal of Pharmacology
Volume128
Issue number3
DOIs
StatePublished - Nov 9 1999

Fingerprint

Anaphylatoxin C5a Receptor
Neutropenia
Hypotension
Inhibitory Concentration 50
Complement C5a
Macrophages
Blood Pressure
Peritoneal Macrophages
Neutrophils
complement C5a, (65-74), Tyr(65)-Phe(67)-Pro(69,71)-Ala(73)-
In Vitro Techniques

Keywords

  • C5a
  • C5a agonist
  • Hypotension
  • Neutropenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Short, A. J., Paczkowski, N. J., Vogen, S. M., Sanderson, S. D., & Taylor, S. M. (1999). Response-selective C5a agonists: Differential effects on neutropenia and hypotension in the rat. British Journal of Pharmacology, 128(3), 511-514. https://doi.org/10.1038/sj.bjp.0702847

Response-selective C5a agonists : Differential effects on neutropenia and hypotension in the rat. / Short, Anna J.; Paczkowski, Natalii J.; Vogen, Shawn M.; Sanderson, Sam D.; Taylor, Stephen M.

In: British Journal of Pharmacology, Vol. 128, No. 3, 09.11.1999, p. 511-514.

Research output: Contribution to journalArticle

Short, Anna J. ; Paczkowski, Natalii J. ; Vogen, Shawn M. ; Sanderson, Sam D. ; Taylor, Stephen M. / Response-selective C5a agonists : Differential effects on neutropenia and hypotension in the rat. In: British Journal of Pharmacology. 1999 ; Vol. 128, No. 3. pp. 511-514.
@article{60c3be79a20f4a16989656c018be3477,
title = "Response-selective C5a agonists: Differential effects on neutropenia and hypotension in the rat",
abstract = "Some in vivo activities of two complement C5a agonist analogues have been evaluated by measuring changes in blood pressure and neutropenia in the rat and comparing the results with their receptor affinities in peritoneal macrophages and polymorphonuclear leucocytes (PMNs). In vitro C5a receptor (C5aR) binding experiments showed that YSFKPMPLaR and YSFKD(NMeNle)PlaR had similar affinities for the macrophage C5aR (IC50 0.2, 0.1 μM respectively). In PMNs, the affinity of YSFKPMPLaR (IC50 0.1 μM) was similar to that in macrophages, whereas the affinity of YSFKD(NMeNle)PLaR for the PMN C5aR was > 100 μM. Given i.v., YSFKD(NMeNle)PLaR had similar activity to YSFKPMPLaR on blood pressure but did not cause neutropenia. These results demonstrate selectivity of a new C5a agonist in vitro, which is paralleled in vivo. The results suggest the possibility of developing selective agonists of C5a for in vivo use in humans.",
keywords = "C5a, C5a agonist, Hypotension, Neutropenia",
author = "Short, {Anna J.} and Paczkowski, {Natalii J.} and Vogen, {Shawn M.} and Sanderson, {Sam D.} and Taylor, {Stephen M.}",
year = "1999",
month = "11",
day = "9",
doi = "10.1038/sj.bjp.0702847",
language = "English (US)",
volume = "128",
pages = "511--514",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Response-selective C5a agonists

T2 - Differential effects on neutropenia and hypotension in the rat

AU - Short, Anna J.

AU - Paczkowski, Natalii J.

AU - Vogen, Shawn M.

AU - Sanderson, Sam D.

AU - Taylor, Stephen M.

PY - 1999/11/9

Y1 - 1999/11/9

N2 - Some in vivo activities of two complement C5a agonist analogues have been evaluated by measuring changes in blood pressure and neutropenia in the rat and comparing the results with their receptor affinities in peritoneal macrophages and polymorphonuclear leucocytes (PMNs). In vitro C5a receptor (C5aR) binding experiments showed that YSFKPMPLaR and YSFKD(NMeNle)PlaR had similar affinities for the macrophage C5aR (IC50 0.2, 0.1 μM respectively). In PMNs, the affinity of YSFKPMPLaR (IC50 0.1 μM) was similar to that in macrophages, whereas the affinity of YSFKD(NMeNle)PLaR for the PMN C5aR was > 100 μM. Given i.v., YSFKD(NMeNle)PLaR had similar activity to YSFKPMPLaR on blood pressure but did not cause neutropenia. These results demonstrate selectivity of a new C5a agonist in vitro, which is paralleled in vivo. The results suggest the possibility of developing selective agonists of C5a for in vivo use in humans.

AB - Some in vivo activities of two complement C5a agonist analogues have been evaluated by measuring changes in blood pressure and neutropenia in the rat and comparing the results with their receptor affinities in peritoneal macrophages and polymorphonuclear leucocytes (PMNs). In vitro C5a receptor (C5aR) binding experiments showed that YSFKPMPLaR and YSFKD(NMeNle)PlaR had similar affinities for the macrophage C5aR (IC50 0.2, 0.1 μM respectively). In PMNs, the affinity of YSFKPMPLaR (IC50 0.1 μM) was similar to that in macrophages, whereas the affinity of YSFKD(NMeNle)PLaR for the PMN C5aR was > 100 μM. Given i.v., YSFKD(NMeNle)PLaR had similar activity to YSFKPMPLaR on blood pressure but did not cause neutropenia. These results demonstrate selectivity of a new C5a agonist in vitro, which is paralleled in vivo. The results suggest the possibility of developing selective agonists of C5a for in vivo use in humans.

KW - C5a

KW - C5a agonist

KW - Hypotension

KW - Neutropenia

UR - http://www.scopus.com/inward/record.url?scp=0032699864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032699864&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0702847

DO - 10.1038/sj.bjp.0702847

M3 - Article

C2 - 10516626

AN - SCOPUS:0032699864

VL - 128

SP - 511

EP - 514

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 3

ER -